Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration

Summary

This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.

Timeline

Start

2026-05-19

Primary completion

2028-05

Completion

2028-05

Drugs

Indications